Cutler Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cutler Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-25,000	Closed	-$172K	–	112
2019 Q3	$172K	Sell	25,000 -81,697	-77%	-$626K	0.06%	110
2019 Q2	$984K	Buy	106,697 +17,169	+19%	+$207K	0.4%	65
2019 Q1	$1.4M	Sell	89,528 -75,156	-46%	-$1.33M	0.58%	55
2018 Q4	$2.54M	Buy	+164,684	New	+$3.38M	1.15%	30
2018 Q1	–	Sell	-7,000	Closed	-$133K	–	107
2017 Q4	$133K	Buy	7,000 +100	+1%	+$1.5K	0.05%	99
2017 Q3	$121K	Buy	6,900 +2,900	+73%	+$65.3K	0.05%	89
2017 Q2	$133K	Buy	+4,000	New	+$124K	0.06%	76

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Cutler Capital Management's TEVA Position: Q4 2019 in Review

Cutler Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 25,000 shares — an estimated $172K sold.

Cutler Capital Management first reported a position in TEVA in Q2 2017 and held it in 7 quarters. The position peaked at $2.54M in Q4 2018. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Cutler Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Cutler Capital Management sold 25,000 Teva Pharmaceuticals shares in Q4 2019, an estimated $172K.
Cutler Capital Management first reported a position in Teva Pharmaceuticals in Q2 2017 and held it in 7 quarters.
Cutler Capital Management's Teva Pharmaceuticals position peaked at $2.54M in Q4 2018.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Cutler Capital Management's 13F filing for Q4 2019, filed 10 Feb 2020.